Indivior Pharmaceuticals Inc (INDV) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
18.33
+5% vs avg
5yr avg: 17.51
30Y Low1.0·High28.0
P/FCF
↑
N/A
—
5yr avg: 122.25
30Y Low2.7·High15.6
P/B Ratio
↑
N/A
—
5yr avg: 36.04
30Y Low1.9·High59.0
ROE
↓
N/A
—
5yr avg: 54.6%
30Y Low-102%·High398%
Debt/EBITDA
↑
1.23
↓-57% vs avg
5yr avg: 2.87
30Y Low0.7·High6.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INDV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Indivior Pharmaceuticals Inc trades at 24.8x earnings, 95% below its 5-year average of 486.7x, sitting at the 67th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 12%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.1B | $4.6B | $1.7B | $2.2B | $3.0B | $2.7B | $1.1B | $393M | $1.0B | $4.1B | $2.6B |
| Enterprise Value | $5.2B | $4.7B | $1.7B | $2.1B | $2.5B | $1.8B | $504M | $-374213840 | $331M | $3.7B | $2.5B |
| P/E Ratio → | 24.76 | 21.88 | 828.67 | 1082.98 | — | 13.17 | — | 2.83 | 3.86 | 67.07 | 80.68 |
| P/S Ratio | 4.09 | 3.71 | 1.39 | 1.98 | 3.36 | 3.36 | 1.67 | 0.50 | 1.06 | 3.59 | 2.72 |
| P/B Ratio | — | — | — | — | 58.97 | 13.11 | 13.14 | 1.88 | 15.36 | — | — |
| P/FCF | — | — | 236.17 | — | — | 8.34 | — | 2.73 | 4.05 | 15.55 | 7.74 |
| P/OCF | — | — | 45.92 | — | — | 7.54 | — | 2.60 | 3.50 | 13.28 | 7.08 |
P/E links to full P/E history page with 30-year chart
INDV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Indivior Pharmaceuticals Inc's enterprise value stands at 18.3x EBITDA, roughly in line with its 5-year average of 17.5x. The Healthcare sector median is 14.1x, placing the stock at a 30% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.83 | 1.44 | 1.95 | 2.80 | 2.33 | 0.78 | -0.48 | 0.34 | 3.25 | 2.56 |
| EV / EBITDA | 18.33 | 16.66 | 28.02 | — | — | 7.85 | — | -1.82 | 1.00 | 8.55 | 7.07 |
| EV / EBIT | 19.71 | 16.72 | 31.08 | — | — | 8.54 | — | -1.85 | 1.12 | 19.36 | 18.19 |
| EV / FCF | — | — | 244.17 | — | — | 5.78 | — | -2.60 | 1.32 | 14.11 | 7.28 |
INDV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Indivior Pharmaceuticals Inc earns an operating margin of 21.4%. Operating margins have expanded from -14.3% to 21.4% over the past 3 years, signaling improving operational efficiency. ROIC of 342.7% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 80.1% | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% | 82.2% | 86.0% | 89.3% | 88.6% |
| Operating Margin | 21.4% | 21.4% | 2.7% | -14.3% | -9.0% | 26.9% | -24.1% | 22.7% | 33.0% | 36.9% | 34.9% |
| Net Profit Margin | 16.9% | 16.9% | 0.2% | -11.8% | -4.9% | 25.9% | -22.9% | 17.1% | 27.4% | 5.3% | 3.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -34.6% | 143.9% | -101.7% | 97.5% | 398.0% | — | — |
| ROA | 16.6% | 16.6% | 0.1% | -7.3% | -2.4% | 12.2% | -9.3% | 8.4% | 17.6% | 4.6% | 2.7% |
| ROIC | 342.7% | 342.7% | — | — | — | — | — | — | — | — | — |
| ROCE | 79.1% | 79.1% | 7.5% | -25.4% | -9.1% | 21.7% | -16.9% | 21.7% | 48.1% | 110.1% | 188.8% |
INDV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Indivior Pharmaceuticals Inc carries a Debt/EBITDA ratio of 1.2x, which is manageable (62% below the sector average of 3.3x). Net debt stands at $156M ($351M total debt minus $195M cash). Interest coverage of 6.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 5.40 | 1.41 | 3.48 | 1.40 | 3.65 | — | — |
| Debt / EBITDA | 1.23 | 1.23 | 6.15 | — | — | 1.22 | — | 1.42 | 0.73 | 1.10 | 1.53 |
| Net Debt / Equity | — | — | — | — | -9.77 | -4.02 | -6.99 | -3.67 | -10.35 | — | — |
| Net Debt / EBITDA | 0.55 | 0.55 | 0.92 | — | — | -3.47 | — | -3.72 | -2.05 | -0.87 | -0.45 |
| Debt / FCF | — | — | 8.00 | — | — | -2.56 | — | -5.33 | -2.73 | -1.44 | -0.46 |
| Interest Coverage | 6.31 | 6.31 | 1.34 | -3.26 | -2.14 | 8.31 | -6.21 | 9.18 | 9.52 | 3.94 | 2.68 |
INDV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.71x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.98x to 0.71x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.71 | 0.71 | 0.89 | 0.98 | 1.24 | 1.80 | 1.98 | 1.83 | 1.62 | 1.43 | 0.96 |
| Quick Ratio | 0.55 | 0.55 | 0.70 | 0.88 | 1.12 | 1.68 | 1.83 | 1.73 | 1.53 | 1.37 | 0.92 |
| Cash Ratio | 0.21 | 0.21 | 0.34 | 0.32 | 0.88 | 1.37 | 1.43 | 1.43 | 1.13 | 1.01 | 0.67 |
| Asset Turnover | — | 1.03 | 0.90 | 0.62 | 0.51 | 0.43 | 0.42 | 0.48 | 0.62 | 0.80 | 0.80 |
| Inventory Turnover | 1.61 | 1.61 | 1.30 | 1.29 | 1.32 | 1.34 | 1.04 | 1.92 | 1.73 | 2.36 | 2.70 |
| Days Sales Outstanding | — | 75.12 | 78.04 | 84.82 | 89.12 | 93.21 | 123.55 | 94.85 | 105.71 | 81.70 | 77.23 |
INDV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Indivior Pharmaceuticals Inc returns 0.2% to shareholders annually primarily through share buybacks. The earnings yield of 4.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 2.4% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 197.1% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.0% | 4.6% | 0.1% | 0.1% | — | 7.6% | — | 35.4% | 25.9% | 1.5% | 1.2% |
| FCF Yield | — | — | 0.4% | — | — | 12.0% | — | 36.7% | 24.7% | 6.4% | 12.9% |
| Buyback Yield | 0.2% | 0.2% | 10.5% | 1.5% | 3.0% | 3.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.2% | 0.2% | 10.5% | 1.5% | 3.0% | 3.8% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% |
| Shares Outstanding | — | $128M | $133M | $142M | $139M | $154M | $147M | $151M | $150M | $150M | $149M |
Peer Comparison
Compare INDV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INDVYou | $5B | 24.8 | 18.3 | — | 80.1% | 21.4% | — | 342.7% | 1.2 |
 RBBN | $471M | 12.2 | 9.6 | 18.1 | 47.0% | 2.4% | 9.3% | 2.1% | 5.0 |
 AVPT | $2B | 68.5 | 44.5 | 27.2 | 74.1% | 7.9% | 9.4% | 1143.3% | 0.3 |
 BHVN | $1B | -1.5 | — | — | — | — | -310.8% | -242.1% | — |
 ALKS | $6B | 24.7 | 17.2 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 BHC | $2B | 13.1 | 6.4 | 2.1 | 60.9% | 21.3% | 588.2% | 8.2% | 6.1 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 COLL | $1B | 21.1 | 4.5 | 3.6 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 MTLS | $332M | 36.8 | 8.3 | 30.9 | 57.1% | 1.9% | 2.9% | 2.0% | 2.6 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 PCRX | $932M | 148.1 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See INDV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INDV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INDV vs RBBN
Side-by-side business, growth, and profitability comparison vs Ribbon Communications Inc..
Start ComparisonINDV — Frequently Asked Questions
Quick answers to the most common questions about buying INDV stock.
What is Indivior Pharmaceuticals Inc's P/E ratio?
Indivior Pharmaceuticals Inc's current P/E ratio is 24.8x. The historical average is 31.6x. This places it at the 67th percentile of its historical range.
What is Indivior Pharmaceuticals Inc's EV/EBITDA?
Indivior Pharmaceuticals Inc's current EV/EBITDA is 18.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.5x.
Is INDV stock overvalued?
Based on historical data, Indivior Pharmaceuticals Inc is trading at a P/E of 24.8x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Indivior Pharmaceuticals Inc's profit margins?
Indivior Pharmaceuticals Inc has 80.1% gross margin and 21.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Indivior Pharmaceuticals Inc have?
Indivior Pharmaceuticals Inc's Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.